[Treatment of primary fibromyalgia using Rheumajecta and Vasolastine; results of a randomized, placebo-controlled, double-blind study].
Hissink Muller
W
W
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002374:Catalase / Q000627:therapeutic use; D002795:Choline O-Acetyltransferase / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005356:Fibromyalgia / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008049:Lipase / Q000627:therapeutic use*; D008084:Lipoxygenase / Q000627:therapeutic use*; D013430:Sulfate Adenylyltransferase / Q000627:therapeutic use; D013466:Sulfurtransferases / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; C023681:Rheumajecta; C029007:vasoelastine; D002374:Catalase; D008084:Lipoxygenase; D002795:Choline O-Acetyltransferase; D013430:Sulfate Adenylyltransferase; D013466:Sulfurtransferases; D008049:Lipase
Behandeling met Rheumajecta en Vasolastine van primaire fibromyalgie; resultaten van een gerandomiseerd, placebo-gecontroleerd, dubbelblind onderzoek.